Abstract
Randomized phase III trials have demonstrated that the addition of paclitaxel is effective in the adjuvant treatment of breast cancer. Forty-five patients with high-risk resected breast cancer entered this study. They were treated with three cycles of epirubicin every 2 weeks, followed by three cycles of intensified CMF, every 2 weeks, followed 3 weeks later by nine weekly cycles of paclitaxel (E-CMF-T). Forty patients (89%) received all cycles of chemotherapy and dose intensity was sufficiently maintained for all drugs. Toxicity was generally mild to moderate. Two cases of febrile neutropenia were reported. The E-CMF-T regimen is feasible and well tolerated.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / radiotherapy
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Cyclophosphamide / administration & dosage
-
Drug Administration Schedule
-
Epirubicin / administration & dosage
-
Feasibility Studies
-
Female
-
Fluorouracil / administration & dosage
-
Griechenland
-
Humans
-
Mastectomy*
-
Methotrexate / administration & dosage
-
Middle Aged
-
Paclitaxel / administration & dosage
-
Radiotherapy, Adjuvant
-
Risk Assessment
-
Treatment Outcome
Substances
-
Epirubicin
-
Cyclophosphamide
-
Paclitaxel
-
Fluorouracil
-
Methotrexate